|Drug Name:||epirubicin hydrochloride |
|Manufacturer:||OTN Generics Inc.|
|Other Info:||Rx onlyManufactured by:Pfizer (Perth) Pty Limited, Bentley WA 6102 AustraliaManufactured for:OTN Generics Inc.South San Francisco, CA 94080LAB-0351-3.0April 2008|
Epirubicin Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
-- (brest KAN-ser) Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare.
Malignant neoplasm of breast
-- A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males. -- 2003
Patients should not be treated with epirubicin Injection if they have any of the following conditions: baseline neutrophil count < 1500 cells/mm3; severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias; previous treatment with anthracyclines up to the maximum cumulative dose; hypersensitivity to epirubicin, other anthracyclines, or anthracenediones; or severe hepatic dysfunction (see WARNINGS and DOSAGE AND ADMINISTRATION).
-- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
Epirubicin injection should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy.
Before beginning treatment with epirubicin, patients should recover from acute toxicities (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment.
Also, initial treatment with epirubicin should be preceded by a careful baseline assessment of blood counts; serum levels of total bilirubin, AST, and creatinine; and cardiac function as measured by left ventricular ejection function (LVEF).
Patients should be carefully monitored during treatment for possible clinical complications due to myelosuppression.
Supportive care may be necessary for the treatment of severe neutropenia and severe infectious complications.
Monitoring for potential cardiotoxicity is also important, especially with greater cumulative exposure to epirubicin.
The following US Branded drugs contain epirubicin hydrochloride
-- PFIZER INC
This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor.
It should not to be used for self-diagnosis or treatment.